These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384 [TBL] [Abstract][Full Text] [Related]
4. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Johnson A Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638 [TBL] [Abstract][Full Text] [Related]
5. Management of cSSTIs: the role of daptomycin. Garau J Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967 [TBL] [Abstract][Full Text] [Related]
6. [Safety of daptomycin in patients with renal impairment]. Azanza JR; Quetglas EG Med Clin (Barc); 2010 Dec; 135 Suppl 3():55-9. PubMed ID: 21477705 [TBL] [Abstract][Full Text] [Related]
7. Daptomycin: a novel cyclic lipopeptide antimicrobial. Schriever CA; Fernández C; Rodvold KA; Danziger LH Am J Health Syst Pharm; 2005 Jun; 62(11):1145-58. PubMed ID: 15914875 [TBL] [Abstract][Full Text] [Related]
8. [Daptomycin in the treatment of Gram-positive infections in patients with chronic renal failure]. Sarriá Cepeda C Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():38-42. PubMed ID: 22541974 [TBL] [Abstract][Full Text] [Related]
9. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Hair PI; Keam SJ Drugs; 2007; 67(10):1483-512. PubMed ID: 17600394 [TBL] [Abstract][Full Text] [Related]
10. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections]. Mathiesen L; Midtvedt T; Solberg CO Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552 [TBL] [Abstract][Full Text] [Related]
11. Daptomycin: the first approved lipopeptide antimicrobial. Guay DR Consult Pharm; 2004 Jul; 19(7):614-28. PubMed ID: 16553491 [TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Arbeit RD; Maki D; Tally FP; Campanaro E; Eisenstein BI; Clin Infect Dis; 2004 Jun; 38(12):1673-81. PubMed ID: 15227611 [TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
14. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Gould IM; Miró JM; Rybak MJ Int J Antimicrob Agents; 2013 Sep; 42(3):202-10. PubMed ID: 23845504 [TBL] [Abstract][Full Text] [Related]
15. Daptomycin: evaluation of a high-dose treatment strategy. Wu G; Abraham T; Rapp J; Vastey F; Saad N; Balmir E Int J Antimicrob Agents; 2011 Sep; 38(3):192-6. PubMed ID: 21549573 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Benvenuto M; Benziger DP; Yankelev S; Vigliani G Antimicrob Agents Chemother; 2006 Oct; 50(10):3245-9. PubMed ID: 17005801 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study. Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225 [TBL] [Abstract][Full Text] [Related]
20. [Daptomycin, the first cydal antibiotic of a new class active against Gram positive pathogens]. Stefani S; Esposito S Infez Med; 2006 Dec; 14(4):179-96. PubMed ID: 17380085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]